BRPI0720500A8 - Preparação líquida transdérmica - Google Patents

Preparação líquida transdérmica

Info

Publication number
BRPI0720500A8
BRPI0720500A8 BRPI0720500A BRPI0720500A BRPI0720500A8 BR PI0720500 A8 BRPI0720500 A8 BR PI0720500A8 BR PI0720500 A BRPI0720500 A BR PI0720500A BR PI0720500 A BRPI0720500 A BR PI0720500A BR PI0720500 A8 BRPI0720500 A8 BR PI0720500A8
Authority
BR
Brazil
Prior art keywords
liquid preparation
transdermal liquid
cattle
methods
preparation
Prior art date
Application number
BRPI0720500A
Other languages
English (en)
Inventor
Meadows Cheyney
Alan Freehauf Keith
D Simmons Robert
J Weingarten Allan
Original Assignee
Schering Plough Ltd
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd, Intervet Int Bv filed Critical Schering Plough Ltd
Publication of BRPI0720500A2 publication Critical patent/BRPI0720500A2/pt
Publication of BRPI0720500A8 publication Critical patent/BRPI0720500A8/pt
Publication of BRPI0720500B1 publication Critical patent/BRPI0720500B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS E MÉTODOS PARA TRATAR INFLAMAÇÃO EM GADO E OUTROS ANIMAIS. São descritas novas preparações transdérmicas que combinam um fármaco anti-inflamatório não esteroidal (NSAID) tal como flunixina. Também são descritos métodos para usar e administrar tal preparação no tratamento de condições inflamatórias em bovinos, incluindo doença respiratória bovina.
BRPI0720500A 2006-12-20 2007-12-18 preparação líquida transdérmica BRPI0720500B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87090706P 2006-12-20 2006-12-20
US60/870,907 2006-12-20
PCT/US2007/025808 WO2008082507A2 (en) 2006-12-20 2007-12-18 Pharmaceutical compositions and method for treating inflammation in cattle and other animals

Publications (3)

Publication Number Publication Date
BRPI0720500A2 BRPI0720500A2 (pt) 2014-02-04
BRPI0720500A8 true BRPI0720500A8 (pt) 2015-12-29
BRPI0720500B1 BRPI0720500B1 (pt) 2019-01-02

Family

ID=39262615

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720500A BRPI0720500B1 (pt) 2006-12-20 2007-12-18 preparação líquida transdérmica

Country Status (19)

Country Link
US (1) US9006272B2 (pt)
EP (1) EP2120860B1 (pt)
JP (1) JP5377326B2 (pt)
KR (1) KR20090091328A (pt)
CN (2) CN101588789B (pt)
AR (1) AR064425A1 (pt)
AU (1) AU2007339312B2 (pt)
BR (1) BRPI0720500B1 (pt)
CA (1) CA2672964C (pt)
CL (1) CL2007003711A1 (pt)
CO (1) CO6190598A2 (pt)
ES (1) ES2714550T3 (pt)
MX (1) MX2009006893A (pt)
NZ (1) NZ598554A (pt)
PE (1) PE20081406A1 (pt)
RU (1) RU2466715C2 (pt)
TW (1) TWI350182B (pt)
WO (1) WO2008082507A2 (pt)
ZA (1) ZA200904329B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738970A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
EP2544662B1 (en) 2010-03-10 2020-05-20 Nuvo Pharmaceuticals Inc. Foamable formulation
WO2012022837A1 (en) * 2010-08-16 2012-02-23 Helsingin Yliopisto Transdermal compositions
JP5827954B2 (ja) * 2010-09-30 2015-12-02 富山化学工業株式会社 経皮吸収製剤
JP7032037B2 (ja) * 2013-02-27 2022-03-08 ロバート バット ローリー 経皮製剤
CN105769827B (zh) * 2016-03-09 2018-07-17 金陵科技学院 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法
KR20200065711A (ko) 2018-11-30 2020-06-09 한원경 동물 피부질환 개선용 조성물
WO2021010843A1 (en) 2019-07-16 2021-01-21 Donaghys Limited Transdermal solvent system and methods of use
WO2021045870A1 (en) * 2019-09-06 2021-03-11 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
EP4251205A1 (en) * 2020-11-25 2023-10-04 Intervet International B.V. Method of treatment of pain through buccal administration of flunixin
WO2022238965A1 (en) * 2021-05-12 2022-11-17 Argenta Innovation Limited Veterinary transdermal formulation
CN114404360B (zh) * 2021-12-16 2023-03-28 江西益昕葆生物科技有限公司 一种氟尼辛葡甲胺注射液的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225316A (ja) * 1986-10-21 1988-09-20 Nitto Electric Ind Co Ltd 外皮投与用組成物
JPH11222443A (ja) * 1997-11-11 1999-08-17 Saitama Daiichi Seiyaku Kk 経皮吸収促進組成物および経皮吸収製剤
AU1780101A (en) * 1999-11-19 2001-05-30 Xel Herbaceuticals Transdermal delivery system for alkaloids of aconitum species
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
WO2005009510A2 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
CA2533101A1 (en) 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
CA2573412A1 (en) * 2004-07-19 2006-02-02 Warner-Lambert Company Llc Formulation for stimulating hair growth
EP1791522A1 (en) * 2004-09-16 2007-06-06 Bayer HealthCare AG Dermally applicable formulations for treating skin diseases in animals
NZ568313A (en) * 2005-11-21 2011-11-25 Schering Plough Ltd Pharmaceutical compositions comprising buprenorphine

Also Published As

Publication number Publication date
PE20081406A1 (es) 2008-10-17
ES2714550T3 (es) 2019-05-29
EP2120860B1 (en) 2019-01-23
CO6190598A2 (es) 2010-08-19
ZA200904329B (en) 2010-05-26
TWI350182B (en) 2011-10-11
BRPI0720500B1 (pt) 2019-01-02
JP2010513500A (ja) 2010-04-30
RU2009127500A (ru) 2011-01-27
EP2120860A2 (en) 2009-11-25
WO2008082507A3 (en) 2009-03-19
WO2008082507A2 (en) 2008-07-10
CA2672964A1 (en) 2008-07-10
CN103690471B (zh) 2015-11-18
AU2007339312A1 (en) 2008-07-10
BRPI0720500A2 (pt) 2014-02-04
CN101588789A (zh) 2009-11-25
KR20090091328A (ko) 2009-08-27
AU2007339312B2 (en) 2013-06-06
US20080153885A1 (en) 2008-06-26
CA2672964C (en) 2018-04-03
CL2007003711A1 (es) 2008-07-25
CN101588789B (zh) 2013-12-11
TW200833367A (en) 2008-08-16
NZ598554A (en) 2013-08-30
AR064425A1 (es) 2009-04-01
JP5377326B2 (ja) 2013-12-25
US9006272B2 (en) 2015-04-14
CN103690471A (zh) 2014-04-02
MX2009006893A (es) 2009-07-03
RU2466715C2 (ru) 2012-11-20

Similar Documents

Publication Publication Date Title
BRPI0720500A8 (pt) Preparação líquida transdérmica
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
DE602007006815D1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxyü-piperidin-1-carbonsäure isopropyl ester als stoffwechselmodulatore und behandlung von damit assoziierten erkrankungen
EA200971053A1 (ru) Способы лечения кожных язв
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
WO2008109119A3 (en) Wnt compositions and methods of use thereof
BRPI0509271A (pt) formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
EA200702280A1 (ru) Синергические комбинации
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
EA200500941A1 (ru) Средство для лечения болезней суставов
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
DK1585513T3 (da) Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INTERVET INTERNATIONAL B. V. (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS.